PMGC Holdings (ELAB) Free Cash Flow (2022 - 2026)
PMGC Holdings (ELAB) posted Free Cash Flow of -$3.3 million for Q1 2026, down 59.43% sequentially from -$2.1 million in Q4 2025, and down 148.08% YoY from $7.0 million in Q1 2025.
PMGC Holdings (ELAB) Free Cash Flow (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Free Cash Flow for 5 years, with the latest figure at -$3.3 million in Q1 2026.
- Quarterly Free Cash Flow fell 148.08% year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 83.49% YoY) and the FY2025 annual result came in at -$6.4 million, down 16.01% from the prior year.
- Free Cash Flow eased to -$3.3 million in Q1 2026 per ELAB's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $1.1 billion in Q4 2022 and troughed at -$3.3 million in Q1 2026.
- A 5-year average of $78.2 million and a median of -$1.3 million in 2025 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 42.25% in 2025, down 290.43% in 2025.
- Over 5 years, Free Cash Flow stood at $1.1 billion in 2022, then slumped by 100.21% to -$2.4 million in 2023, then grew by 16.23% to -$2.0 million in 2024, then declined by 4.8% to -$2.1 million in 2025, then tumbled by 59.43% to -$3.3 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$3.3 million, -$2.1 million, and -$1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -1.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.34 Mn |
| Mar 31, 2026 | -3.34 Mn |
| Dec 31, 2025 | -2.10 Mn |
| Dec 31, 2025 | -2.10 Mn |
| Sep 30, 2025 | -1.49 Mn |
| Sep 30, 2025 | -1.49 Mn |
| Jun 30, 2025 | -1.35 Mn |
| Jun 30, 2025 | -1.35 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | -381,678.00 |
| Sep 30, 2024 | -381,678.00 |
| Jun 30, 2024 | -780,689.00 |
| Jun 30, 2024 | -780,689.00 |
| Mar 31, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.33 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Dec 31, 2023 | -2.39 Mn |